
Mark D Stegall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1991839/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)–Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	1.9	9
2	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
3	The Kidney in Normal Aging. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 137-139.	4.5	15
4	Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 414-422.	4.5	3
5	Healthy and unhealthy aging on kidney structure and function. Current Opinion in Nephrology and Hypertension, 2022, Publish Ahead of Print, .	2.0	5
6	Death With Function and Graft Failure After Kidney Transplantation: Risk Factors at Baseline Suggest New Approaches to Management. Transplantation Direct, 2022, 8, e1273.	1.6	9
7	Endoscopic Ultrasound–Guided Dual Ultrasound Hepatic Cyst Aspiration and Sclerotherapy to Ameliorate Portal Hypertension. American Journal of Gastroenterology, 2022, 117, 715-716.	0.4	1
8	Kidney glomerular filtration rate plasticity after transplantation. CKJ: Clinical Kidney Journal, 2022, 15, 841-844.	2.9	1
9	Clinical and Kidney Structural Characteristics of Living Kidney Donors With Nephrolithiasis and Their Long-term Outcomes. Transplantation Direct, 2022, 8, e1278.	1.6	2
10	Automated Segmentation of Kidney Cortex and Medulla in CT Images: A Multisite Evaluation Study. Journal of the American Society of Nephrology: JASN, 2022, 33, 420-430.	6.1	13
11	Complications After Hand-Assisted Laparoscopic Living Donor Nephrectomy. Mayo Clinic Proceedings, 2022, 97, 894-904.	3.0	2
12	Sodiumâ€glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation. Clinical Transplantation, 2022, 36, e14718.	1.6	11
13	Guiding Kidney Transplantation Candidates for Effective Weight Loss: A Clinical Cohort Study. Kidney360, 2022, 3, 1411-1416.	2.1	5
14	Convolutional Neural Networks for the Evaluation of Chronic and Inflammatory Lesions in Kidney Transplant Biopsies. American Journal of Pathology, 2022, 192, 1418-1432.	3.8	16
15	Trajectories of glomerular filtration rate and progression to end stage kidney disease afterÂkidney transplantation. Kidney International, 2021, 99, 186-197.	5.2	40
16	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney International, 2021, 99, 707-715.	5.2	13
17	Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. Transplantation, 2021, 105, 436-442.	1.0	3
18	Mesangial expansion at 5 years predicts death and deathâ€censored graft loss after renal transplantation. Clinical Transplantation, 2021, 35, e14147.	1.6	2

#	Article	IF	CITATIONS
19	Estimating alloantibody levels in highly sensitized renal allograft candidates: Using serial dilutions to demonstrate a treatment effect in clinical trials. American Journal of Transplantation, 2021, 21, 1278-1284.	4.7	12
20	Chronic graft-versus-host disease in pancreas after kidney transplant recipients – An unrecognized entity. American Journal of Transplantation, 2021, 21, 883-888.	4.7	2
21	Kidney Microstructural Features at the Time of Donation Predict Long-term Risk of Chronic Kidney Disease in Living Kidney Donors. Mayo Clinic Proceedings, 2021, 96, 40-51.	3.0	24
22	Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation. American Journal of Transplantation, 2021, 21, 1612-1621.	4.7	11
23	Renal function outcomes and kidney biopsy features of living kidney donors with hypertension. Clinical Transplantation, 2021, 35, e14293.	1.6	4
24	Implication of TIGIT+ human memory B cells in immune regulation. Nature Communications, 2021, 12, 1534.	12.8	41
25	Kidney Histology, Kidney Function, and Age. American Journal of Kidney Diseases, 2021, 77, 312-314.	1.9	3
26	Current Approaches to Desensitization in Solid Organ Transplantation. Frontiers in Immunology, 2021, 12, 686271.	4.8	14
27	A Higher Foci Density of Interstitial Fibrosis and Tubular Atrophy Predicts Progressive CKD after a Radical Nephrectomy for Tumor. Journal of the American Society of Nephrology: JASN, 2021, 32, 2623-2633.	6.1	21
28	Tests for the noninvasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs. American Journal of Transplantation, 2021, 21, 3811.	4.7	4
29	Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function. American Journal of Transplantation, 2021, , .	4.7	2
30	1H Nuclear Magnetic Resonance Spectroscopy-Based Methods for the Quantification of Proteins in Urine. Analytical Chemistry, 2021, 93, 13177-13186.	6.5	2
31	Acute Kidney Injury in Severe COVID-19 Has Similarities to Sepsis-Associated Kidney Injury. Mayo Clinic Proceedings, 2021, 96, 2561-2575.	3.0	41
32	Antibody-Mediated Rejection: the Role of Plasma Cells and Memory B Cells. Current Transplantation Reports, 2021, 8, 272-280.	2.0	0
33	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. The Lancet Digital Health, 2021, 3, e795-e805.	12.3	25
34	Progressive decline of function in renal allografts with normal one year biopsies: Gene expression studies fail to identify a classifier. Clinical Transplantation, 2021, , e14456.	1.6	0
35	Authors' Reply. Journal of the American Society of Nephrology: JASN, 2021, 32, 517-518.	6.1	3
36	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. Transplantation, 2021, 105, 1615-1624.	1.0	0

#	Article	IF	CITATIONS
37	P.157: NK and B Cell Subset Assessment in Type I Diabetes Patients on Waitlist for Pancreas Transplantation. Transplantation, 2021, 105, S65-S65.	1.0	0
38	P.138: Patients Report Improved Diabetes Distress After Successful Pancreas Transplantation. Transplantation, 2021, 105, S56-S56.	1.0	0
39	P.155: Altered T Cell Compartment in Type 1 Diabetes With End Stage Renal Disease. Transplantation, 2021, 105, S63-S64.	1.0	0
40	P.140: Impact of Successful Pancreas Transplantation on Patient Reported Hypoglycemia Outcomes. Transplantation, 2021, 105, S57-S57.	1.0	0
41	Mesangial matrix expansion in a novel mouse model of diabetic kidney disease associated with the metabolic syndrome. Journal of Nephropathology, 2021, 10, e17-e17.	0.2	1
42	Comparison of high glomerular filtration rate thresholds for identifying hyperfiltration. Nephrology Dialysis Transplantation, 2020, 35, 1017-1026.	0.7	14
43	Ten Years of Kidney Paired Donation at Mayo Clinic: The Benefits of Incorporating ABO/HLA Compatible Pairs. Transplantation, 2020, 104, 1229-1238.	1.0	19
44	The need for novel trial designs, master protocols, and research consortia in transplantation. Clinical Transplantation, 2020, 34, e13759.	1.6	11
45	Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function. Journal of the American Society of Nephrology: JASN, 2020, 31, 2642-2652.	6.1	30
46	Obesity-Related Glomerulopathy and Single-Nephron GFR. Kidney International Reports, 2020, 5, 1126-1128.	0.8	12
47	Kidney Structural Features from Living Donors Predict Graft Failure in the Recipient. Journal of the American Society of Nephrology: JASN, 2020, 31, 415-423.	6.1	29
48	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 2318-2331.	4.7	437
49	The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients. Transplantation Direct, 2020, 6, e524.	1.6	33
50	Phenotypic, Transcriptional, and Functional Analysis of Liver Mesenchymal Stromal Cells and Their Immunomodulatory Properties. Liver Transplantation, 2020, 26, 549-563.	2.4	9
51	Chronic Histologic Changes Are Present Regardless of HLA Mismatches. Transplantation, 2020, Publish Ahead of Print, e244-e256.	1.0	1
52	Glomerular Volume and Glomerulosclerosis at Different Depths within the Human Kidney. Journal of the American Society of Nephrology: JASN, 2019, 30, 1471-1480.	6.1	39
53	Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization?. Clinical Transplantation, 2019, 33, e13751.	1.6	48
54	Larger nephron size, low nephron number, and nephrosclerosis on biopsy as predictors of kidney function after donating a kidney. American Journal of Transplantation, 2019, 19, 1989-1998.	4.7	39

#	Article	IF	CITATIONS
55	Continuous glucose monitoring to assess glycemic control in the first 6 weeks after pancreas transplantation. Clinical Transplantation, 2019, 33, e13719.	1.6	11
56	Patient experience after kidney transplant: a conceptual framework of treatment burden. Journal of Patient-Reported Outcomes, 2019, 3, 8.	1.9	23
57	Deep Learning–Based Histopathologic Assessment of Kidney Tissue. Journal of the American Society of Nephrology: JASN, 2019, 30, 1968-1979.	6.1	226
58	Preoperative Factors Predicting Admission to the Intensive Care Unit After Kidney Transplantation. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 285-293.	2.4	9
59	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ: British Medical Journal, 2019, 366, 14923.	2.3	191
60	Global Glomerulosclerosis in Kidney Biopsies With Differing Amounts of Cortex: A Clinical-Pathologic Correlation Study. Kidney Medicine, 2019, 1, 153-161.	2.0	8
61	Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. Journal of the American Society of Nephrology: JASN, 2019, 30, 1206-1219.	6.1	85
62	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. American Journal of Transplantation, 2019, 19, 2876-2888.	4.7	95
63	The Relationship Between Frailty and Decreased Physical Performance With Death on the Kidney Transplant Waiting List. Progress in Transplantation, 2019, 29, 108-114.	0.7	27
64	Using computer-assisted morphometrics of 5-year biopsies to identify biomarkers of late renal allograft loss. American Journal of Transplantation, 2019, 19, 2846-2854.	4.7	13
65	Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials. American Journal of Transplantation, 2019, 19, 2274-2283.	4.7	2
66	In-vivo techniques for determining nephron number. Current Opinion in Nephrology and Hypertension, 2019, 28, 545-551.	2.0	18
67	Transplantation in the Sensitized Recipient and Across ABO Blood Groups. , 2019, , 355-366.		Ο
68	Clinical outcomes after ABO-incompatible renal transplantation. Lancet, The, 2019, 394, 1988-1989.	13.7	3
69	Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post–kidney Transplantation: A Consecutive Series of 15 Cases. Transplantation, 2019, 103, 2397-2404.	1.0	49
70	A method to reduce variability in scoring antibody-mediated rejection in renal allografts: implications for clinical trials - a retrospective study. Transplant International, 2019, 32, 173-183.	1.6	24
71	The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement. American Journal of Transplantation, 2019, 19, 625-632.	4.7	17
72	Factors at de novo donorâ€specific antibody initial detection associated with allograft loss: a multicenter study. Transplant International, 2019, 32, 502-515.	1.6	16

#	Article	IF	CITATIONS
73	Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. American Journal of Transplantation, 2019, 19, 1671-1683.	4.7	48
74	Obesity and Metabolic Syndrome in Kidney Transplantation: The Role of Dietary Fructose and Systemic Endotoxemia. Transplantation, 2019, 103, 191-201.	1.0	5
75	Donor-specific hypo-responsiveness occurs in simultaneous liver-kidney transplant recipients after the first year. Kidney International, 2018, 93, 1465-1474.	5.2	41
76	De novo donorâ€specific antibody following <scp>BK</scp> nephropathy: The incidence and association with antibodyâ€mediated rejection. Clinical Transplantation, 2018, 32, e13194.	1.6	35
77	Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study. American Journal of Transplantation, 2018, 18, 650-658.	4.7	11
78	Long-term Immunosuppression Adherence After Kidney Transplant and Relationship to Allograft Histology. Transplantation Direct, 2018, 4, e392.	1.6	3
79	Identifying Barriers to Preemptive Kidney Transplantation in a Living Donor Transplant Cohort. Transplantation Direct, 2018, 4, e356.	1.6	16
80	Clinical and Pathology Findings Associate Consistently with Larger Glomerular Volume. Journal of the American Society of Nephrology: JASN, 2018, 29, 1960-1969.	6.1	33
81	The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging. Journal of the American Society of Nephrology: JASN, 2017, 28, 313-320.	6.1	272
82	Risk of Hypertension among First-Time Symptomatic Kidney Stone Formers. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 476-482.	4.5	39
83	Unique molecular changes in kidney allografts afterÂsimultaneous liver-kidney compared withÂsolitary kidney transplantation. Kidney International, 2017, 91, 1193-1202.	5.2	48
84	Pancreas transplantation. BMJ: British Medical Journal, 2017, 357, j1321.	2.3	102
85	32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody. Transplantation, 2017, 101, 1222-1227.	1.0	67
86	Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch. Transplantation, 2017, 101, 2429-2439.	1.0	49
87	Single-Nephron Glomerular Filtration Rate in Healthy Adults. New England Journal of Medicine, 2017, 376, 2349-2357.	27.0	247
88	Survival Benefit in Older Patients Associated With Earlier Transplant With High KDPI Kidneys. Transplantation, 2017, 101, 867-872.	1.0	90
89	Relationship between pre-transplant physical function and outcomes after kidney transplant. Clinical Transplantation, 2017, 31, e12952.	1.6	31
90	Effects of Aspirin Therapy on Ultrasound–Guided Renal Allograft Biopsy Bleeding Complications. Journal of Vascular and Interventional Radiology, 2017, 28, 188-194.	0.5	21

#	Article	IF	CITATIONS
91	Single-Nephron Glomerular Filtration Rate in Healthy Adults. New England Journal of Medicine, 2017, 377, 1202-1204.	27.0	14
92	Why do we have the kidney allocation system we have today? A history of the 2014 kidney allocation system. Human Immunology, 2017, 78, 4-8.	2.4	50
93	The conundrums of chronic kidney disease and aging. Journal of Nephrology, 2017, 30, 477-483.	2.0	26
94	Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis. Human Antibodies, 2017, 25, 121-129.	1.5	7
95	Reply to Letter to the Editor. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2017, 39, 347-348.	0.9	0
96	Interpreting Anti-HLA Antibody Testing Data. Transplantation, 2016, 100, 1619-1628.	1.0	52
97	Early subclinical inflammation correlates with outcomes in positive crossmatch kidney allografts. Clinical Transplantation, 2016, 30, 925-933.	1.6	6
98	Reassessing Preemptive Kidney Transplantation in the United States. Transplantation, 2016, 100, 1120-1127.	1.0	70
99	A monoclonal natural human IgM protects axons in the absence of remyelination. Journal of Neuroinflammation, 2016, 13, 94.	7.2	10
100	Pathophysiology of Experimental Autoimmune Encephalomyelitis. , 2016, , 249-280.		3
101	Specific renal parenchymalâ€derived urinary extracellular vesicles identify ageâ€associated structural changes in living donor kidneys. Journal of Extracellular Vesicles, 2016, 5, 29642.	12.2	55
102	Human class I major histocompatibility complex alleles determine central nervous system injury versus repair. Journal of Neuroinflammation, 2016, 13, 293.	7.2	3
103	Tubulointerstitial Fibrosis of Living Donor Kidneys Associates with Urinary Monocyte Chemoattractant Protein 1. American Journal of Nephrology, 2016, 43, 454-459.	3.1	10
104	AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage–Th17 Axis. Journal of Immunology, 2016, 197, 747-760.	0.8	25
105	Predicting Individual Renal Allograft Outcomes Using Risk Models with 1-Year Surveillance Biopsy and Alloantibody Data. Journal of the American Society of Nephrology: JASN, 2016, 27, 3165-3174.	6.1	35
106	Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation. Kidney International, 2016, 89, 909-917.	5.2	83
107	Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. American Journal of Kidney Diseases, 2016, 68, 58-67.	1.9	78
108	Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. New England Journal of Medicine, 2016, 374, 940-950.	27.0	279

#	Article	IF	CITATIONS
109	Structural and Functional Changes With the Aging Kidney. Advances in Chronic Kidney Disease, 2016, 23, 19-28.	1.4	476
110	Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease. Molecular Neurobiology, 2016, 53, 5217-5228.	4.0	22
111	Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts. Transplantation, 2015, 99, 2382-2386.	1.0	39
112	Adherence to a pedometerâ€based physical activity intervention following kidney transplant and impact on metabolic parameters. Clinical Transplantation, 2015, 29, 560-568.	1.6	14
113	Computational Biology: Modeling Chronic Renal Allograft Injury. Frontiers in Immunology, 2015, 6, 385.	4.8	2
114	Distinguishing age-related from disease-related glomerulosclerosis on kidney biopsy: the Aging Kidney Anatomy study. Nephrology Dialysis Transplantation, 2015, 30, 2034-2039.	0.7	90
115	Compensatory Hypertrophy of the Remaining Kidney in Medically Complex Living Kidney Donors Over the Long Term. Transplantation, 2015, 99, 555-559.	1.0	33
116	Obesity Correlates With Glomerulomegaly But Is Not Associated With Kidney Dysfunction Early After Donation. Transplantation Direct, 2015, 1, 1-6.	1.6	10
117	A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 83.	7.2	10
118	A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. DMM Disease Models and Mechanisms, 2015, 8, 831-42.	2.4	38
119	Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice. Nucleic Acid Therapeutics, 2015, 25, 11-19.	3.6	22
120	Through a Glass Darkly. Journal of the American Society of Nephrology: JASN, 2015, 26, 20-29.	6.1	112
121	Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases. JAMA Neurology, 2015, 72, 1346.	9.0	16
122	Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis. Journal of Biological Chemistry, 2015, 290, 30697-30712.	3.4	76
123	Abbreviated Exposure to Hypoxia Is Sufficient to Induce CNS Dysmyelination, Modulate Spinal Motor Neuron Composition, and Impair Motor Development in Neonatal Mice. PLoS ONE, 2015, 10, e0128007.	2.5	18
124	Should We Be Performing More Pancreas Transplants?. Clinical Transplants, 2015, 31, 173-180.	0.2	2
125	Kidney donors at increased risk? Additional studies are needed. Kidney International, 2014, 86, 650.	5.2	8
126	Down-Regulating Humoral Immune Responses. Transplantation, 2014, 97, 247-257.	1.0	16

#	Article	IF	CITATIONS
127	Renal retransplantation after kidney and pancreas transplantation using the renal vessels of the failed allograft: pitfalls and pearls. Clinical Transplantation, 2014, 28, 669-674.	1.6	6
128	Antibody-mediated rejection despite inhibition of terminal complement. Transplant International, 2014, 27, 1235-1243.	1.6	58
129	Differences in Chronic Intragraft Inflammation Between Positive Crossmatch and ABO-Incompatible Kidney Transplantation. Transplantation, 2014, 98, 1089-1096.	1.0	20
130	Genes and Transplant Outcomes. Transplantation, 2014, 98, 257-258.	1.0	5
131	Assessing the Efficacy of Kidney Paired Donation—Performance of an Integrated Three-Site Program. Transplantation, 2014, 98, 300-305.	1.0	21
132	New insights regarding chronic antibody-mediated rejection and its progression to transplant glomerulopathy. Current Opinion in Nephrology and Hypertension, 2014, 23, 611-618.	2.0	22
133	Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases. Expert Review of Neurotherapeutics, 2014, 14, 449-463.	2.8	22
134	Antibody-mediated rejection in liver transplantation: Current controversies and future directions. Liver Transplantation, 2014, 20, 514-527.	2.4	62
135	Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management. Current Transplantation Reports, 2014, 1, 78-85.	2.0	14
136	Polyclonal and Monoclonal Antibodies in Clinic. Methods in Molecular Biology, 2014, 1060, 79-110.	0.9	30
137	Transplantation in the Sensitized Recipient and Across ABO Blood Groups. , 2014, , 360-371.		Ο
138	Deletion of Virus-specific T-cells Enhances Remyelination in a Model of Multiple Sclerosis. , 2014, 2, .		5
139	Therapeutics to Promote CNS Repair: A Natural Human Neuron-Binding IgM Regulates Membrane-Raft Dynamics and Improves Motility in a Mouse Model of Multiple Sclerosis. Journal of Clinical Immunology, 2013, 33, 50-56.	3.8	8
140	Living Donor Kidney Transplantation Using Laparoscopically Procured Multiple Renal Artery Kidneys and Right Kidneys. Journal of the American College of Surgeons, 2013, 217, 144-152.	0.5	30
141	CD8 ⁺ T cells in multiple sclerosis. Expert Opinion on Therapeutic Targets, 2013, 17, 1053-1066.	3.4	76
142	Inter and intra laboratory concordance of HLA antibody results obtained by single antigen bead based assay. Human Immunology, 2013, 74, 310-317.	2.4	12
143	The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment. Expert Review of Clinical Immunology, 2013, 9, 535-549.	3.0	11
144	Minimal effect of bortezomib in reducing antiâ€pig antibodies in human leukocyte antigenâ€sensitized patients: a pilot study. Xenotransplantation, 2013, 20, 429-437.	2.8	5

#	Article	lF	CITATIONS
145	Urine But Not Serum Soluble Urokinase Receptor (suPAR) May Identify Cases of Recurrent FSGS in Kidney Transplant Candidates. Transplantation, 2013, 96, 394-399.	1.0	88
146	Using Implantation Biopsies as a Surrogate to Evaluate Selection Criteria for Living Kidney Donors. Transplantation, 2013, 96, 975-980.	1.0	15
147	Renal ablation using bilateral ureteral ligation for nephrotic syndrome due to renal amyloidosis. CKJ: Clinical Kidney Journal, 2012, 5, 153-154.	2.9	4
148	Antibody-Mediated Injury in the Renal Allograft. , 2012, 17, 219-224.		2
149	Need for a paradigm shift in therapeutic approaches to CNS injury. Expert Review of Neurotherapeutics, 2012, 12, 409-420.	2.8	8
150	Identification and Characterization of Kidney Transplants With Good Glomerular Filtration Rate at 1 Year But Subsequent Progressive Loss of Renal Function. Transplantation, 2012, 94, 931-939.	1.0	32
151	Deletion of Betaâ€2â€Microglobulin Ameliorates Spinal Cord Lesion Load and Promotes Recovery of Brainstem NAA Levels in a Murine Model of Multiple Sclerosis. Brain Pathology, 2012, 22, 698-708.	4.1	13
152	Long-Term Follow-Up of Patients with Monoclonal Gammopathy of Undetermined Significance after Kidney Transplantation. American Journal of Nephrology, 2012, 35, 365-371.	3.1	32
153	Preclinical ¹ H-MRS neurochemical profiling in neurological and psychiatric disorders. Bioanalysis, 2012, 4, 1787-1804.	1.5	20
154	The role of complement in antibody-mediated rejection in kidney transplantation. Nature Reviews Nephrology, 2012, 8, 670-678.	9.6	204
155	The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts. Transplant Immunology, 2012, 27, 95-100.	1.2	11
156	Association of Kidney Function and Metabolic Risk Factors With Density of Glomeruli on Renal Biopsy Samples From Living Donors. Mayo Clinic Proceedings, 2011, 86, 282-290.	3.0	59
157	The relevance of animal models in multiple sclerosis research. Pathophysiology, 2011, 18, 21-29.	2.2	244
158	Abnormal circadian blood pressure pattern 1-year after kidney transplantation is associated with subsequent lower glomerular filtration rate in recipients without rejection. Journal of the American Society of Hypertension, 2011, 5, 39-47.	2.3	22
159	A Single Dose of Neuron-Binding Human Monoclonal Antibody Improves Spontaneous Activity in a Murine Model of Demyelination. PLoS ONE, 2011, 6, e26001.	2.5	20
160	The Impact of Proteasome Inhibition on Alloantibody-Producing Plasma Cells In Vivo. Transplantation, 2011, 91, 536-541.	1.0	68
161	Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis. Neurology Research International, 2011, 2011, 1-14.	1.3	25
162	The effect of coronary angiography on renal function in preemptive renal transplant candidates. Clinical Transplantation, 2011, 25, 594-599.	1.6	6

#	Article	IF	CITATIONS
163	Transgenic Expression of Viral Capsid Proteins Predisposes to Axonal Injury in a Murine Model of Multiple Sclerosis. Brain Pathology, 2011, 21, no-no.	4.1	11
164	An Important Debate. American Journal of Transplantation, 2011, 11, 1758-1758.	4.7	0
165	MRI in Rodent Models of Brain Disorders. Neurotherapeutics, 2011, 8, 3-18.	4.4	76
166	Relationship between FKBP5 polymorphisms and depression symptoms among kidney transplant recipients. Depression and Anxiety, 2011, 28, 1111-1118.	4.1	17
167	Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrology Dialysis Transplantation, 2011, 26, 2032-2036.	0.7	88
168	Free Fatty Acid Storage in Human Visceral and Subcutaneous Adipose Tissue. Diabetes, 2011, 60, 2300-2307.	0.6	53
169	The (re)emergence of B cells in organ transplantation. Current Opinion in Organ Transplantation, 2010, 15, 451-455.	1.6	37
170	Epidemiology of Infections Requiring Hospitalization During Long-Term Follow-Up of Pancreas Transplantation. Transplantation, 2010, 89, 1126-1133.	1.0	38
171	Significance and Implications of Capillaritis During Acute Rejection of Kidney Allografts. Transplantation, 2010, 89, 1088-1094.	1.0	43
172	Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Current Opinion in Organ Transplantation, 2010, 15, 8-10.	1.6	104
173	The Association Between Age and Nephrosclerosis on Renal Biopsy Among Healthy Adults. Annals of Internal Medicine, 2010, 152, 561.	3.9	391
174	Evidence that alloantibody is a major risk factor for graft loss and death in living-donor liver transplantation. Surgery, 2010, 147, 845-846.	1.9	0
175	The Right Kidney for the Right Recipient: The Status of Deceased Donor Kidney Allocation Reform. Seminars in Dialysis, 2010, 23, 248-252.	1.3	10
176	Fibrosis with Inflammation at One Year Predicts Transplant Functional Decline. Journal of the American Society of Nephrology: JASN, 2010, 21, 1987-1997.	6.1	194
177	Sensitized renal transplant recipients: current protocols and future directions. Nature Reviews Nephrology, 2010, 6, 297-306.	9.6	86
178	Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrology Dialysis Transplantation, 2010, 25, 307-310.	0.7	66
179	Prevalence of Renal Artery and Kidney Abnormalities by Computed Tomography among Healthy Adults. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 431-438.	4.5	89
180	Transgenic Expression of the 3D Polymerase Inhibits Theiler's Virus Infection and Demyelination. Journal of Virology, 2009, 83, 12279-12289.	3.4	15

#	Article	IF	CITATIONS
181	Brainstem ¹ H nuclear magnetic resonance (NMR) spectroscopy: Marker of demyelination and repair in spinal cord. Annals of Neurology, 2009, 66, 559-564.	5.3	20
182	Tumor Necrosis Factor α is Reparative via TNFR1 in the Hippocampus and via TNFR2 in the Striatum after Virusâ€Induced Encephalitis. Brain Pathology, 2009, 19, 12-26.	4.1	24
183	Apoptosis of Hippocampal Pyramidal Neurons Is Virus Independent in a Mouse Model of Acute Neurovirulent Picornavirus Infection. American Journal of Pathology, 2009, 175, 668-684.	3.8	58
184	Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis: Outcomes and Response to Therapy for Recurrence. Transplantation, 2009, 87, 1232-1239.	1.0	173
185	Pulmonary Hypertension Is Associated With Reduced Patient Survival After Kidney Transplantation. Transplantation, 2008, 86, 1384-1388.	1.0	114
186	Long-term benefits of pancreas transplantation. Current Opinion in Organ Transplantation, 2008, 13, 85-90.	1.6	55
187	Transplant Glomerulopathy: Risk and Prognosis Related to Anti-Human Leukocyte Antigen Class II Antibody Levels. Transplantation, 2008, 86, 681-685.	1.0	168
188	Kidney Transplant Histology After One Year of Continuous Therapy With Sirolimus Compared With Tacrolimus. Transplantation, 2008, 85, 1212-1215.	1.0	26
189	Transplantation in the Sensitized Recipient and Across ABO Blood Groups. , 2008, , 350-360.		Ο
190	Diurnal Blood Pressure Changes One Year after Kidney Transplantation: Relationship to Allograft Function, Histology, and Resistive Index. Journal of the American Society of Nephrology: JASN, 2007, 18, 1607-1615.	6.1	60
191	The Rationale for the New Deceased Donor Pancreas Allocation Schema. Transplantation, 2007, 83, 1156-1161.	1.0	67
192	ABO incompatible kidney transplantation. Current Opinion in Nephrology and Hypertension, 2007, 16, 529-534.	2.0	38
193	Molecular Evidence of Injury and Inflammation in Normal and Fibrotic Renal Allografts One Year Posttransplant. Transplantation, 2007, 83, 1466-1476.	1.0	36
194	The Effect of Antithymocyte Globulin on Anti–Human Leukocyte Antigen Antibody Detection Assays. Transplantation, 2007, 84, 258-264.	1.0	28
195	Preemptive Living Donor Kidney Transplantation: Do the Benefits Extend to All Recipients?. Transplantation, 2007, 83, 144-149.	1.0	59
196	Comparison of Low Versus High Tacrolimus Levels in Kidney Transplantation: Assessment of Efficacy by Protocol Biopsies. Transplantation, 2007, 83, 411-416.	1.0	81
197	Decreased Incidence of Acute Rejection in Adolescent Kidney Transplant Recipients Using Antithymocyte Induction and Triple Immunosuppression. Transplantation, 2007, 84, 715-721.	1.0	13
198	A meta-analysis of kidney microarray datasets: investigation of cytokine gene detection and correlation with rt-PCR and detection thresholds. BMC Genomics, 2007, 8, 88.	2.8	37

#	Article	IF	CITATIONS
199	Prevalence of Post-Transplant Lymphoproliferative Disorder with Monoclonal Gammopathy of Unknown Significance in Patients Undergoing Kidney Transplantation Blood, 2007, 110, 4778-4778.	1.4	0
200	Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience Blood, 2007, 110, 4779-4779.	1.4	0
201	Overcoming antibody barriers to transplantation: ABO-incompatible and positive cross-match kidney transplantation at Mayo Clinic – Rochester. International Congress Series, 2006, 1292, 113-119.	0.2	Ο
202	Complications, Resource Utilization, and Cost of ABO-Incompatible Living Donor Kidney Transplantation. Transplantation, 2006, 82, 155-163.	1.0	57
203	ABO-Incompatible Kidney Transplantation with and without Splenectomy. Transplantation, 2006, 82, 720.	1.0	15
204	Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrology Dialysis Transplantation, 2006, 21, 2607-2614.	0.7	52
205	Blood Pressure and Renal Function after Kidney Donation from Hypertensive Living Donors. Transplantation, 2005, 79, 1769-1770.	1.0	0
206	A Comparison of Splenectomy versus Intensive Posttransplant Antidonor Blood Group Antibody Monitoring without Splenectomy in ABO-Incompatible Kidney Transplantation. Transplantation, 2005, 80, 1572-1577.	1.0	95
207	Outcome of Untreated Grade II Rejection on Solitary Pancreas Allograft Biopsy Specimens. Transplantation, 2005, 79, 1717-1722.	1.0	19
208	Differences between Early and Late Posttransplant Lymphoproliferative Disorders in Solid Organ Transplant Patients: Are They Two Different Diseases?. Transplantation, 2005, 79, 244-247.	1.0	140
209	Improving the Prediction of Donor Kidney Quality: Deceased Donor Score and Resistive Indices. Transplantation, 2005, 80, 925-929.	1.0	89
210	New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney International, 2005, 67, 2415-2421.	5.2	337
211	United Network for Organ Sharing's expanded criteria donors: is stratification useful?*. Clinical Transplantation, 2005, 19, 406-412.	1.6	44
212	A novel model of allograft rejection: immune reconstitution of Rag-1 recipients with 2C transgenic T-cell receptor lymphocytes. Transplant International, 2005, 18, 101-110.	1.6	3
213	The Development of Kidney Allocation Policy. American Journal of Kidney Diseases, 2005, 46, 974-975.	1.9	15
214	Obesity in Living Kidney Donors: Clinical Characteristics and Outcomes in the Era of Laparoscopic Donor Nephrectomy. American Journal of Transplantation, 2005, 5, 1057-1064.	4.7	150
215	Kidney Allograft Fibrosis and Atrophy Early After Living Donor Transplantation. American Journal of Transplantation, 2005, 5, 1130-1136.	4.7	118
216	Early Subclinical Coronary Artery Calcification in Young Adults Who Were Pediatric Kidney Transplant Recipients. American Journal of Transplantation, 2005, 5, 1689-1693.	4.7	43

#	Article	IF	CITATIONS
217	Living Donor Kidney and Autologous Stem Cell Transplantation for Primary Systemic Amyloidosis (AL) with Predominant Renal Involvement. American Journal of Transplantation, 2005, 5, 1660-1670.	4.7	83
218	Predicting Subsequent Decline in Kidney Allograft Function from Early Surveillance Biopsies. American Journal of Transplantation, 2005, 5, 2464-2472.	4.7	279
219	Conquering absolute contraindications to transplantation: Positive-crossmatch and ABO-incompatible kidney transplantation. Surgery, 2005, 137, 269-273.	1.9	18
220	Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders. Journal of Clinical Oncology, 2005, 23, 7574-7582.	1.6	182
221	Pancreas Transplants: Experience with 232 Percutaneous US-guided Biopsy Procedures in 88 Patients. Radiology, 2004, 231, 845-849.	7.3	66
222	Hand-assisted laparoscopic donor nephrectomy for pediatric kidney allograft recipients. Pediatric Transplantation, 2004, 8, 460-463.	1.0	10
223	Patient and graft outcomes from older living kidney donors are similar to those from younger donors despite lower GFR. Kidney International, 2004, 66, 1654-1661.	5.2	72
224	Should We Be Performing Pancreas Transplants?. American Journal of Transplantation, 2004, 4, 1935-1936.	4.7	2
225	Histologic Findings of Antibody-Mediated Rejection in ABO Blood-Group-Incompatible Living-Donor Kidney Transplantation. American Journal of Transplantation, 2004, 4, 101-107.	4.7	96
226	Correlation of Quantitative Digital Image Analysis with the Glomerular Filtration Rate in Chronic Allograft Nephropathy. American Journal of Transplantation, 2004, 4, 248-256.	4.7	79
227	Measured and estimated GFR in healthy potential kidney donors. American Journal of Kidney Diseases, 2004, 43, 112-119.	1.9	348
228	Tolerance for immunosuppression in organ transplantation. Liver Transplantation, 2004, 10, 573-575.	2.4	0
229	Immunomodulation through inhibition of multiple adhesion molecules generates resistance to autoimmune diabetes in NOD mice. Journal of Autoimmunity, 2004, 23, 201-209.	6.5	8
230	PROSPECTIVE, RANDOMIZED TRIAL OF THE EFFECT OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION: THREE-YEAR RESULTS1. Transplantation, 2004, 77, 1269-1275.	1.0	70
231	Decline in native renal function early after bladder-drained pancreas transplantation alone. Transplantation, 2004, 77, 844-849.	1.0	37
232	Blood Pressure and Renal Function after Kidney Donation from Hypertensive Living Donors. Transplantation, 2004, 78, 276-282.	1.0	142
233	Acute Nephrotoxicity of Tacrolimus and Sirolimus in Renal Isografts: Differential Intragraft Expression of Transforming Growth Factor-??1 and ??-Smooth Muscle Actin. Transplantation, 2004, 78, 338-344.	1.0	48
234	Pancreas-after-kidney transplantation: an increasingly attractive alternative to simultaneous pancreas-kidney transplantation. Transplantation, 2004, 77, 838-843.	1.0	36

#	Article	IF	CITATIONS
235	WOUND-HEALING COMPLICATIONS AFTER KIDNEY TRANSPLANTATION: A PROSPECTIVE, RANDOMIZED COMPARISON OF SIROLIMUS AND TACROLIMUS1. Transplantation, 2004, 77, 1555-1561.	1.0	284
236	ABO-Incompatible Kidney Transplantation. Transplantation, 2004, 78, 635-640.	1.0	119
237	Persistence of Low Levels of Alloantibody after Desensitization in Crossmatch-Positive Living-Donor Kidney Transplantation. Transplantation, 2004, 78, 221-227.	1.0	95
238	ABO-incompatible liver transplant: Is it justifiable?. Liver Transplantation, 2003, 9, 31.	2.4	13
239	Forskolin suppresses insulin gene transcription in islet β-cells through a protein kinase A-independent pathway. Cellular Signalling, 2003, 15, 27-35.	3.6	18
240	Improved Scoring System to Assess Adult Donors For Cadaver Renal Transplantation. American Journal of Transplantation, 2003, 3, 715-721.	4.7	170
241	Prospective, Randomized, Multi-Center Trial of Antibody Induction Therapy in Simultaneous Pancreas-Kidney Transplantation. American Journal of Transplantation, 2003, 3, 855-864.	4.7	52
242	Accommodation in ABO-Incompatible Kidney Allografts, a Novel Mechanism of Self-Protection Against Antibody-Mediated Injury. American Journal of Transplantation, 2003, 3, 952-960.	4.7	177
243	Overcoming a Positive Crossmatch in Livingâ€Đonor Kidney Transplantation. American Journal of Transplantation, 2003, 3, 1017-1023.	4.7	239
244	Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney International, 2003, 64, 665-673.	5.2	157
245	Blood Pressure Evaluation among Older Living Kidney Donors. Journal of the American Society of Nephrology: JASN, 2003, 14, 2159-2167.	6.1	57
246	Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation, 2003, 75, 2048-2053.	1.0	128
247	ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation, 2003, 75, 971-977.	1.0	187
248	Subclinical Rejection in Tacrolimus-Treated Renal Transplant Recipients. Transplantation, 2002, 73, 1965-1967.	1.0	101
249	Changes in intragraft gene expression secondary to ischemia reperfusion after cardiac transplantation. Transplantation, 2002, 74, 924-930.	1.0	26
250	Survival of mandatorily shared cadaveric kidneys and their paybacks in the zero mismatch era. Transplantation, 2002, 74, 670-675.	1.0	31
251	Prospective, randomized evaluation of a cuffed expanded polytetrafluoroethylene graft for hemodialysis vascular access. Surgery, 2002, 132, 135-140.	1.9	72
252	Can a Transplanted Living Donor Kidney Function Equivalently to its Native Partner?. American Journal of Transplantation, 2002, 2, 252-259.	4.7	33

#	Article	IF	CITATIONS
253	Gene Expression During Acute Allograft Rejection: Novel Statistical Analysis of Microarray Data. American Journal of Transplantation, 2002, 2, 913-925.	4.7	46
254	Chronic renal dysfunction late after liver transplantation. Liver Transplantation, 2002, 8, 916-921.	2.4	134
255	Preliminary Experience with a Cuffed ePTFE Graft for Hemodialysis Vascular Access. ASAIO Journal, 2001, 47, 333-337.	1.6	22
256	??4 INTEGRIN IN ISLET ALLOGRAFT REJECTION1. Transplantation, 2001, 71, 1549-1555.	1.0	18
257	RANDOMIZED TRIAL OF TACROLIMUS PLUS MYCOPHENOLATE MOFETIL OR AZATHIOPRINE VERSUS CYCLOSPORINE ORAL SOLUTION (MODIFIED) PLUS MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION: RESULTS AT 2 YEARS1. Transplantation, 2001, 72, 245-250.	1.0	126
258	Steroid-sparing regimens in organ transplantation. Current Opinion in Organ Transplantation, 2001, 6, 313-319.	1.6	3
259	Cyclosporine elimination in the presence of TOR inhibitors: Effects on renal function, acute rejection, and safety. American Journal of Kidney Diseases, 2001, 38, S3-S10.	1.9	14
260	Donor Scoring System for Cadaveric Renal Transplantation. American Journal of Transplantation, 2001, 1, 162-170.	4.7	82
261	Donor Scoring System for Cadaveric Renal Transplantation. American Journal of Transplantation, 2001, 1, 162.	4.7	1
262	THYMOGLOBULIN INDUCTION DECREASES REJECTION IN SOLITARY PANCREAS TRANSPLANTATION. Transplantation, 2001, 72, 1671-1675.	1.0	23
263	PRELIMINARY EXPERIENCE WITH A CUFFED ePTFE GRAFT FOR HEMODIALYSIS VASCULAR ACCESS. ASAIO Journal, 2000, 46, 216.	1.6	0
264	Pancreas Transplantation for the Prevention of Diabetic Nephropathy. Mayo Clinic Proceedings, 2000, 75, 49-56.	3.0	11
265	RANDOMIZED TRIAL OF TACROLIMUS (PROGRAF) IN COMBINATION WITH AZATHIOPRINE OR MYCHOPHENOLATE MOFETIL VERSUS CYCLOSPORINE (NEORAL) WITH MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION1, 2. Transplantation, 2000, 69, 834-841.	1.0	270
266	Corticosteroid withdrawal in solid organ transplantation. Transplantation Reviews, 1998, 12, 140-147.	2.9	3
267	MYCOPHENOLATE MOFETIL DECREASES REJECTION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION WHEN COMBINED WITH TACROLIMUS OR CYCLOSPORINE1. Transplantation, 1997, 64, 1695-1700.	1.0	85
268	PREDNISONE WITHDRAWAL 14 DAYS AFTER LIVER TRANSPLANTATION WITH MYCOPHENOLATE. Transplantation, 1997, 64, 1755-1760.	1.0	129
269	Autoimmune Destruction of Islet Grafts in the NOD Mouse Is Resistant to 15-Deoxyspergualin but Sensitive to Anti-CD4 Antibody. Journal of Surgical Research, 1996, 64, 156-160.	1.6	17
270	Islet and Pancreatic Transplantation — Autoimmunity and Alloimmunity. New England Journal of Medicine, 1996, 335, 888-890.	27.0	34

#	Article	IF	CITATIONS
271	EVIDENCE OF RECURRENT AUTOIMMUNITY IN HUMAN ALLOGENEIC ISLET TRANSPLANTATION. Transplantation, 1996, 61, 1272-1274.	1.0	109
272	RISK FACTORS FOR PRIMARY DYSFUNCTION AFTER LIVER TRANSPLANTATION—A MULTIVARIATE ANALYSIS. Transplantation, 1993, 55, 807-813.	1.0	937
273	RETRANSPLANTATION OF THE LIVER—A SEVEN-YEAR EXPERIENCE. Transplantation, 1993, 55, 1083-1086.	1.0	110
274	INTERSTITIAL CLASS II-POSITIVE CELL DEPLETION BY DONOR PRETREATMENT WITH GAMMA IRRADIATION. Transplantation, 1990, 49, 246-250.	1.0	29
275	IMPROVED RESULTS USING OKT3 AS INDUCTION IMMUNOSUPPRESSION IN RENAL ALLOGRAFT RECIPIENTS WITH DELAYED GRAFT FUNCTION. Transplantation, 1990, 49, 321-326.	1.0	58
276	HUMORAL IMMUNITY IN ALLOGRAFT REJECTION. Transplantation, 1989, 48, 751-755.	1.0	26
277	PANCREATIC ISLET TRANSPLANTATION IN CYNOMOLGUS MONKEYS. Transplantation, 1989, 48, 944-950.	1.0	32